Alcidion Group (ALC) H2 2026 earnings summary

Executive summary

• Achieved record FY26 financial performance with revenue of $51.6M (up 27%), increased customer base, and strategic acquisition of Kyra flow products, consolidating leadership in patient flow markets.

• Underlying EBITDA rose 34% to $6.8M, with NPAT up 38% to $2.3M and positive operating cash flow, maintaining a debt-free position.

• Expanded presence in Australia, New Zealand, the UK, and made progress in Canada and the Middle East, with major contracts signed in both core regions.

• Secured major long-term contracts and renewals, including University Hospitals Sussex, Gold Coast Health, Leidos (ADF), and North Cumbria NHS.

• Kyra acquisition added 33 customers (31 new), immediately earnings accretive and strengthening Queensland presence.

Financial highlights

• FY26 revenue reached $51.6M, up 27% year-over-year, with recurring revenue up 23% and non-recurring implementation/services revenue up 56%.

• Annual recurring revenue (ARR) as of June 30, 2026, was $38.3M, up 34% year-over-year, including $3.6M from Kyra acquisition.

• Gross profit increased 15% to $41.5M, with gross margin at 80.3% (down from 88.2% in FY25) due to third-party product resales.

• Net profit after tax (NPAT) increased 38% to $2.3M.

• Ended the year with $20.6M in cash and no debt.

Outlook and guidance

• Entering FY27 with $44.9M in contracted and renewal revenue, up 32% from FY26, providing strong visibility for continued growth.

• Revenue and underlying EBITDA for FY27 are expected to exceed FY26, supported by a strong pipeline and recurring revenue base.

• Guidance does not rely on winning another large EPR contract; pipeline is broad and deep.

• Gross margin expected to normalize to mid-80% range in FY27.

• Increased marketing spend planned to support growth in new geographies while maintaining operational leverage.